|Benefit-Cost Summary Statistics Per Participant|
|Taxpayers||$246||Benefits minus costs||($25,220)|
|Participants||$567||Benefit to cost ratio||($0.45)|
|Others||$7||Chance the program will produce|
|Indirect||($8,635)||benefits greater than the costs||0 %|
|Net program cost||($17,406)|
|Benefits minus cost||($25,220)|
|Meta-Analysis of Program Effects|
|Outcomes measured||Treatment age||No. of effect sizes||Treatment N||Adjusted effect sizes(ES) and standard errors(SE) used in the benefit - cost analysis||Unadjusted effect size (random effects model)|
|First time ES is estimated||Second time ES is estimated|
Alcohol use disorder
Clinical diagnosis of alcohol use disorder or symptoms measured on a validated scale.
|Detailed Monetary Benefit Estimates Per Participant|
|Affected outcome:||Resulting benefits:1||Benefits accrue to:|
|Alcohol use disorder||Criminal justice system||$0||$0||$0||$0||$0|
|Labor market earnings associated with alcohol abuse or dependence||$239||$560||$0||$0||$799|
|Health care associated with alcohol abuse or dependence||$5||$1||$6||$3||$15|
|Property loss associated with alcohol abuse or dependence||$0||$1||$1||$0||$2|
|Mortality associated with alcohol||$2||$5||$0||$66||$73|
|Program cost||Adjustment for deadweight cost of program||$0||$0||$0||($8,703)||($8,703)|
|Detailed Annual Cost Estimates Per Participant|
|Annual cost||Year dollars||Summary|
|Program costs||$16,356||2015||Present value of net program costs (in 2018 dollars)||($17,406)|
|Comparison costs||$0||2015||Cost range (+ or -)||10 %|
Benefits Minus Costs
Benefits by Perspective
Taxpayer Benefits by Source of Value
|Benefits Minus Costs Over Time (Cumulative Discounted Dollars)|
|The graph above illustrates the estimated cumulative net benefits per-participant for the first fifty years beyond the initial investment in the program. We present these cash flows in discounted dollars. If the dollars are negative (bars below $0 line), the cumulative benefits do not outweigh the cost of the program up to that point in time. The program breaks even when the dollars reach $0. At this point, the total benefits to participants, taxpayers, and others, are equal to the cost of the program. If the dollars are above $0, the benefits of the program exceed the initial investment.|
Finigan, M.W., Perkins, T., Zold-Kilbourn, P., Parks, J., & Stringer, M. (2011). Preliminary evaluation of extended-release naltrexone in Michigan and Missouri drug courts. Journal of Substance Abuse Treatment, 41(3), 288-293.
Garbutt, J.C., Kranzler, H.R., O'Malley, S.S., Gastfriend, D.R., Pettinati, H.M., Silverman, B.L., . . . Erich, E.W. (2005). Efficacy and tolerability of long-acting injectable naltrexone for alcohol use disorder: A randomized controlled trial. JAMA, 293(13), 1617-1625.
Kranzler, H.R., Wesson, D.R., & Billot, L. (2004). Naltrexone depot for treatment of alcohol use disorder: A multicenter, randomized, placebo-controlled clinical trial. Alcoholism: Clinical and Experimental Research, 28(7), 1051-1059.
Kranzler, H.R., Modesto-Lowe, V., & Nuwayser, E.S. (1998). Sustained-release naltrexone for alcoholism treatment: A preliminary study. Alcoholism: Clinical and Experimental Research, 22(5), 1074-1079.
Pettinati, H.M., Kampman, K.M., Lynch, K.G., Dundon, W.D., Mahoney, E.M., Wierzbicki, M.R., & O'Brien, C.P. (2014). A pilot trial of injectable, extended-release naltrexone for the treatment of co-occurring cocaine and alcohol use disorder. The American Journal on Addictions, 23(6), 591-597.